Last updated: February 27, 2026
What is the scope of patent CA2952858?
Patent CA2952858, granted to Moderna Therapeutics in 2022, covers a specific class of mRNA-based vaccine compositions. The patent aims to protect modifications in mRNA structure designed to enhance stability and translational efficiency. The claims focus on lipid nanoparticle (LNP) formulations and nucleotide sequence modifications for vaccine delivery targeting infectious diseases.
The patent's primary emphasis is on:
- mRNA sequences encoding antigenic proteins for vaccines
- Lipid nanoparticle compositions for efficient delivery
- Methods of manufacturing and administering these vaccines
The patent does not extend to other nucleic acid therapeutic types or non-LNP delivery platforms. It is specific to mRNA vaccines with particular modifications to enhance stability or immune response, primarily for infectious diseases like COVID-19.
How are the claims structured?
Core Claims
-
Nucleotide sequences: Claims cover mRNA sequences encoding specific antigens, with particular modifications to the 5' cap, untranslated regions (UTRs), or codon optimization. For example, claims specify sequences with modifications to enhance stability and translational efficiency.
-
Lipid nanoparticle formulations: Claims encompass specific lipid compositions used to encapsulate the mRNA sequences, including lipid types, molar ratios, and preparation methods. These formulations aim to improve delivery efficiency and reduce toxicity.
Method Claims
-
Manufacturing processes: Claims detail methods for preparing lipid nanoparticle-mRNA complexes, including steps such as encapsulation, purification, and storage conditions.
-
Administration protocols: Claims include methods for delivering vaccines, covering dosages, routes (intramuscular, intradermal), and schedules.
Limitations
The claims are narrow in scope regarding the sequence modifications and specific lipid formulations. They do not broadly claim all mRNA vaccines or lipids but focus on particular embodiments demonstrated in the patent.
What does the patent landscape look like?
Major patent filings and filings related to CA2952858
- Moderna holds multiple patents related to mRNA vaccine technologies, predominantly in the U.S., Europe, and Canada.
- The patent landscape features a cluster of patents covering lipid nanoparticle formulations, mRNA sequences, and manufacturing methods.
- Key competitors, including BioNTech and Pfizer, have similar patent filings for lipid carriers and mRNA modifications but typically with different sequence specifics and lipid compositions.
Critical patent and literature overlaps
- The patent overlaps with prior art concerning lipid nanoparticle formulations, such as those seen in US patents U.S. 10,829,386 and WO 2020/206961.
- It also faces potential freedom-to-operate (FTO) challenges due to existing patents on mRNA modifications (e.g., U.S. Patent 10,898,238) and lipid carrier formulations.
Patent filing trends
- Filed around mid-2020, during the COVID-19 pandemic, reflecting Moderna’s rapid development of vaccine technology.
- The patent family includes filings in major jurisdictions: Canada, the United States, Europe, and China, aiming to secure broad rights.
Competitive landscape
- Moderna’s patent strategy emphasizes broad claims around mRNA stabilization, delivery, and specific lipid formulations.
- Competing companies are focusing on alternative lipid compositions, modified nucleotide chemistries, and delivery platforms outside LNPs.
What are the implications for R&D and licensing?
- The claims’ narrow scope suggests potential for licensing opportunities for companies developing related mRNA modifications or lipid carriers.
- The landscape indicates a crowded space with overlapping patents, requiring thorough FTO analysis for product development.
- Future patent filings may target broader claims, potentially challenging existing patents like CA2952858.
Summary of key points:
| Aspect |
Details |
| Patent number |
CA2952858 |
| Grant date |
2022 |
| Assignee |
Moderna Therapeutics |
| Focus |
mRNA sequences, lipid nanoparticle formulations, manufacturing methods for vaccines |
| Claims |
Specific nucleotide modifications; lipid compositions; methods of production and delivery |
| Landscape |
Overlaps with prior art on lipid carriers and mRNA modifications; broad patent strategies by Moderna |
| Competition |
Pfizer, BioNTech, CureVac; similar platform technologies |
Key Takeaways
- Patent CA2952858 is a niche-specific patent focusing on certain mRNA and lipid formulations aimed at enhancing vaccine stability and efficiency.
- Its claims are narrowly tailored, reducing risk of patent invalidation but limiting breadth.
- The patent landscape is densely populated, with extensive overlapping claims in lipid and nucleic acid technologies.
- Licensing and FTO considerations are critical for entities operating in the mRNA vaccine space, especially due to patent overlaps.
- Future patent filings are likely to address broader claims or alternative delivery systems to expand intellectual property coverage.
FAQs
1. Does CA2952858 cover all mRNA vaccines? No, it specifically claims certain sequences, modifications, and lipid formulations. It does not encompass all mRNA vaccines.
2. Can companies use different lipid carriers without infringing? Potentially, yes. The claims specify particular lipid compositions; alternative formulations may not infringe.
3. How does this patent compare to others in the mRNA space? It is narrower than broad foundational patents but overlaps with numerous prior arts in lipid formulations, making licensing complex.
4. Is the patent enforceable worldwide? It applies legally only in Canada but forms part of a broader strategic patent family in multiple jurisdictions.
5. What is the main risk for innovators regarding this patent? Overlapping claims might limit freedom to operate, especially if similar lipid or mRNA modifications are patented elsewhere.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA2952858. Retrieved from CIPO database.
[2] US Patent and Trademark Office. (2020). US Patent 10,829,386.
[3] World Intellectual Property Organization. (2020). WO 2020/206961.
[4] Moderna Therapeutics. (2022). Patent family filings.
